Dr. Reddy's Laboratories Limited (BVMF:R1DY34)

Market Cap	60.74B -18.0%
Revenue (ttm)	21.20B +11.1%
Net Income	3.47B +5.4%
EPS	4.16 +5.6%
Shares Out	n/a
PE Ratio	17.51
Forward PE	22.51
Dividend	0.06 (0.52%)
Ex-Dividend Date	Jul 9, 2025

Volume	41
Average Volume	194
Open	12.18
Previous Close	12.20
Day's Range	12.18 - 12.18
52-Week Range	11.62 - 14.13
Beta	0.29
RSI	42.67
Earnings Date	Jan 21, 2026

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 27,811
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: R1DY34

Financial Performance

In fiscal year 2025, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.

Financial numbers in INR